
Hyperfine (HYPR) Stock Forecast & Price Target
Hyperfine (HYPR) Analyst Ratings
Bulls say
Hyperfine is currently experiencing strong revenue growth and margin improvement, driven by its innovative Swoop MRI technology which has shown high concordance with standard MRI and received accreditation and regulatory approval. With its expanding international presence, strong pipeline for AI-powered software releases, and a business model that generates both upfront equipment revenue and recurring service revenue, the company is well-positioned for future success. However, it faces potential challenges from supplier pricing pressure, regulatory risks, and slow adoption of its technology.
Bears say
Hyperfine is a medical device company with a negative outlook due to competitive risks and slower revenue ramp-up than expected. While the company's technology provides a unique solution for accessing MRIs and has secured several regulatory clearances, it faces challenges in gaining market share in a highly competitive industry dominated by larger players. Additionally, the company's revenue growth has been slower than expected, with higher international sales mix driving down average selling prices. These factors may hinder the company's ability to meet its revenue and cash burn guidance, making it a risky investment at this time.
This aggregate rating is based on analysts' research of Hyperfine and is not a guaranteed prediction by Public.com or investment advice.
Hyperfine (HYPR) Analyst Forecast & Price Prediction
Start investing in Hyperfine (HYPR)
Order type
Buy in
Order amount
Est. shares
0 shares